Literature DB >> 2936105

Stereoselective synthesis of 5,6,7-trinor-4,8-inter-m-phenylene-PGI2 derivatives and their inhibitory activities to human platelet aggregation.

K Ohno, H Nagase, K Matsumoto, H Nishiyama, S Nishio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2936105

Source DB:  PubMed          Journal:  Adv Prostaglandin Thromboxane Leukot Res        ISSN： 0732-8141


× No keyword cloud information.
  10 in total

1.  Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.

Authors:  Keiyu Oshida; Masahiro Shimamura; Kazuhiro Seya; Akihiro Ando; Yohei Miyamoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

2.  Scalable and safe synthetic organic electroreduction inspired by Li-ion battery chemistry.

Authors:  Byron K Peters; Kevin X Rodriguez; Solomon H Reisberg; Sebastian B Beil; David P Hickey; Yu Kawamata; Michael Collins; Jeremy Starr; Longrui Chen; Sagar Udyavara; Kevin Klunder; Timothy J Gorey; Scott L Anderson; Matthew Neurock; Shelley D Minteer; Phil S Baran
Journal:  Science       Date:  2019-02-22       Impact factor: 47.728

3.  Suppression of pseudointimal hyperplasia by a novel prostacyclin analogue: beraprost.

Authors:  D I Kim; J Kambayashi; T Shibuya; M Sakon; T Kawasaki; T Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

4.  Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina.

Authors:  K Sakata; T Hoshino; H Yoshida; T Kaburagi; A Takada
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

5.  The contractile mechanism of beraprost sodium, a stable prostacyclin analog, in the isolated canine femoral vein.

Authors:  M Ishikawa; A Namiki
Journal:  Heart Vessels       Date:  1994       Impact factor: 2.037

6.  A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design.

Authors:  Hidetomo Nakamoto; Toshiro Fujita; Hideki Origasa; Masanao Isono; Hajimu Kurumatani; Kiyonobu Okada; Hiroyuki Kanoh; Takashi Kiriyama; Shunsuke Yamada
Journal:  BMC Nephrol       Date:  2014-09-19       Impact factor: 2.388

7.  Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.

Authors:  Akio Koyama; Toshiro Fujita; Fumitake Gejyo; Hideki Origasa; Masanao Isono; Hajimu Kurumatani; Kiyonobu Okada; Hiroyuki Kanoh; Takashi Kiriyama; Shunsuke Yamada
Journal:  BMC Nephrol       Date:  2015-10-16       Impact factor: 2.388

8.  Synthesis of novel IP agonists via N-aminoethyl cyclic amines prepared by decarboxylative ring-opening reactions.

Authors:  Yasuhiro Morita; Takeshi Ishigaki; Kuniaki Kawamura; Ryoji Hayashi; Masafumi Isogaya; Mika Kitsukawa; Mitsuko Miyamoto; Masashi Uchida; Katsuhiko Iseki
Journal:  Molecules       Date:  2012-01-31       Impact factor: 4.411

9.  Ameliorative Effect of Beraprost Sodium on Celecoxib Induced Cardiotoxicity in Rats.

Authors:  Shafique Ahmad; Bibhu Prasad Panda; Mohammad Fahim; Neha Dhyani; Kiran Dubey
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

10.  Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or nephrosclerosis: Analysis of the Japanese subgroup in CASSIOPEIR study.

Authors:  Hajimu Kurumatani; Kiyonobu Okada; Hideki Origasa; Toshiro Fujita; Masanao Isono; Hidetomo Nakamoto
Journal:  Ther Apher Dial       Date:  2021-02-21       Impact factor: 1.762
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.